Menopause

In a recent study, postmenopausal women in lower Tertiles of Estradiol concentration experienced an increased prevalence of abdominal aortic calcification.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

In a recent study, only 22.7% of women had menopause symptoms documented in their electronic health record, highlighting low rates of diagnosis and treatment.

A recent study reveals that localized estrogen treatment significantly improves vaginal atrophy and vaginitis symptoms in postmenopausal women, offering new insights into tailored hormone therapies.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

New research shows fezolinetant significantly reduces the frequency and severity of hot flashes in Hispanic women, offering a safer alternative to hormone replacement therapy.

A new study highlights gestational hypertension as a significant predictor of cardiovascular disease in menopausal women, challenging previous assumptions about preeclampsia’s role.

The FDA upped the recommended rate of liver blood tests for patients initiating fezolinetant on the basis of a post-marketing case report involving serious liver injury.

PH80 nasal spray shows promise in reducing menopausal hot flashes, offering an effective and safe non-hormonal treatment option.

At the 2024 Annual Meeting of The Menopause Society, the positive safety and efficacy data of fezolinetant against sleep disturbances from the SKYLIGHT 1 and 2 trials was presented.

Low rates of hormone therapy use have been reported among midlife women, stagnating after decreases in the immediate aftermath of the Women’s Health Initiative.

A new study presented at the 2024 Annual Meeting of The Menopause Society shows hormone therapy remains beneficial for women over 65, helping manage menopause symptoms like hot flashes and improving quality of life.

In this video from The Menopause Society Annual Meeting, Lauren Streicher, MD, talks about what to ask your patients about sexual function.

In a recent study presented at the 2024 Annual Meeting of The Menopause Society, insulin resistance was significantly reduced among postmenopausal women receiving hormone therapy vs placebo.

At the 2024 Menopause Society meeting, JoAnn Pinkerton, MD, highlighted phase 3 long-term safety data of elinzanetant from the OASIS 3 trial.

A discussion of vasomotor symptoms and the potential benefits of elinzanetant with Nanette Santoro, MD, from The Menopause Society annual meeting in Chicago, Illinois.

A new study presented at the 2024 Annual Meeting of the Menopause Society found cognitive behavioral therapy can effectively address sexual concerns during menopause, improving overall well-being.

Nanette Santoro, MD, and Lauren Streicher, MD, MSCP, briefly highlight why they feel the annual Menopause Society is a great place for learning and collaboration.

In a recent study presented at the 2024 Annual Meeting of The Menopause Society, women with certain adverse outcomes during pregnancy had an increased risk of cardiovascular disease later in life.

Female veterans with PTSD are twice as likely to experience early menopause and related health risks, according to a study presented at the 2024 Annual Meeting of The Menopause Society.

In a recent study presented at the 2024 Annual Meeting of The Menopause Society, 59% of nocturnal hot flashes occurred during the second half of the night, a time linked to increased cardiovascular disease risk.

A study presented at the 2024 Annual Meeting of The Menopause Society, found that women who reported physical intimate partner violence also demonstrated decreased working memory performance over time.

Data presented at the 2024 Annual Meeting of The Menopause Society highlighted greater reductions in hot flash severity among women receiving clinical hypnosis compared to those receiving cognitive behavioral therapy.

In a recent study, reduced aging discrepancies were observed in postmenopausal women reporting hormone therapy use vs nonusers.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Astellas Pharma has announced the first dose administration of fezolinetant to manage moderate to severe vasomotor symptoms in breast cancer patients using adjuvant endocrine therapy.

A significant connection has been identified between severe menopause symptoms and cognitive impairment in postmenopausal women, according to findings from a study published in Menopause, the journal of The Menopause Society.

A recent study found that women with a shorter reproductive lifespan had increased odds of multimorbidity compared to those with a longer reproductive lifespan, indicating a need to assess reproductive factors to determine high-risk patients.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Bayer has submitted a New Drug Application for elinzanetant, following positive results from the OASIS studies, showing significant safety and efficacy in treating moderate-to-severe vasomotor symptoms in menopausal women.